Review



cell-specific staining of hepatocytes (cebpa)  (Curiochips inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Curiochips inc cell-specific staining of hepatocytes (cebpa)
    In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of <t>hepatocytes</t> <t>(CEBPA)</t> and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in <xref ref-type=Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant. " width="250" height="auto" />
    Cell Specific Staining Of Hepatocytes (Cebpa), supplied by Curiochips inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell-specific+staining+of+hepatocytes+(cebpa)/cell+specific+staining+of+hepatocytes++cebpa+/pmc11550169-135-21-16
    Average 90 stars, based on 1 article reviews
    cell-specific staining of hepatocytes (cebpa) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids"

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids

    Journal: Gastro Hep Advances

    doi: 10.1016/j.gastha.2024.08.004

    In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in <xref ref-type=Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant. " title="... differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant.

    Techniques Used: In Situ, Fluorescence, Imaging, Staining, Ex Situ, Gene Expression, Activity Assay

    Related Articles

    In Situ:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Fluorescence:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Imaging:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Staining:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Ex Situ:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Gene Expression:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Activity Assay:

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).



    Similar Products

    cell-specific staining of hepatocytes (cebpa)  (Curiochips inc)
    90
    Curiochips inc cell-specific staining of hepatocytes (cebpa)
    In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of <t>hepatocytes</t> <t>(CEBPA)</t> and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in <xref ref-type=Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant. " width="250" height="auto" />
    Cell Specific Staining Of Hepatocytes (Cebpa), supplied by Curiochips inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell-specific+staining+of+hepatocytes+(cebpa)/cell+specific+staining+of+hepatocytes++cebpa+/pmc11550169-135-21-16
    Average 90 stars, based on 1 article reviews
    cell-specific staining of hepatocytes (cebpa) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in <xref ref-type=Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant. " width="100%" height="100%">

    Journal: Gastro Hep Advances

    Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids

    doi: 10.1016/j.gastha.2024.08.004

    Figure Lengend Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant.

    Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).

    Techniques: In Situ, Fluorescence, Imaging, Staining, Ex Situ, Gene Expression, Activity Assay